The Column - February 2008 - (Page 6)

News The Column www.thecolumn.eu.com February 2008 News Calling all French-speaking writers HPLC LC•GC en français launches in June 2008 and is currently sourcing articles written in the French language from scientists across all disciplines of separation science. Whatever your specialization, we’d like to hear from you. If you would like further information and details on how to submit an article, please contact Janet Kelsey, Editor (jkelsey@advanstar.com). Please note that all articles submitted will undergo a review and editing process and be checked for scientific accuracy. workshops 2008 A series of HPLC workshops, sponsored by Hichrom, will be taking place at various locations across the UK throughout 2008. The series commences with two workshops titled, “The Analysis of Protein Therapeutic Drugs by HPLC” and “Introduction to HPLC”, which are being held throughout April in Cambridge, Cardiff and Guildford. Further courses including HPLC Troubleshooting, Validation of HPLC Methods, LC–MS for Chromatographers, Method Development and Advanced Method Development will be held later on in the year at various locations. The trainers for the courses include John Dolan (Editor of LC Troubleshooting for LC•GC Europe), David Carr, Mel Euerby and Tom Jupille who are all experts considered to be at the forefront of the industry. For more detailed information on these courses or a course brochure please contact Hichrom at seminars@hichrom.co.uk Whatman acquisition announced GE Healthcare and Whatman have announced an acquisition agreement pending final approval by shareholders and customary regulatory approvals. GE Healthcare will acquire Whatman for approximately £363 million, with the shareholders in Whatman’s stock receiving £2.70 for each share. Whatman supplies filtration products and technologies globally and boasts a wide product offering of filters and membranes for laboratory, research, life sciences and medical technology applications. GE Healthcare’s Life Sciences business provides technologies for cellular and protein science research as well as tools used in the manufacture of biopharmaceuticals such as vaccines, cell therapies and antibodies. This strategic fit between the two companies is aimed at creating synergies through complementary product and service offerings. The president and CEO of GE Healthcare, Joe Hogan, commented on Links: 6 the acquisition stating, “Whatman’s product offerings are highly complementary with our Life Sciences business; we believe that combining the skills and knowledge of the two businesses will create significant added value for our customers.” It is intended that the transaction will be implemented by way of a scheme of arrangement under UK law. The directors of Whatman, who are voting their shares in favour of the transaction, have unanimously recommended it, with (the largest shareholder of the company) Hermes Focus Asset Management holding approximately 15% of the outstanding shares also agreeing to vote in favour of the transaction. This acquisition is expected to be completed in the second quarter of 2008. For further details on this acquisition please visit GE Healthcare’s website at www.gehealthcare.com www.lcgcenfrancais.fr www.gehealthcare.com www.hichrom.co.uk http://www.thecolumn.eu.com http://www.gehealthcare.com http://www.hichrom.co.uk http://www.lcgcenfrancais.fr http://www.gehealthcare.com

Table of Contents for the Digital Edition of The Column - February 2008

The Column - February 2008
Contents
News
Zosimus
The Winning Hand
Market Trends and Analysis
Comprehensive GC with Quadrupole Mass Spectrometric Detection
Tips and Tricks: GPC/SEC

The Column - February 2008